Dr Miriam Jackson

PhD (2010) Sydney
Postdoctoral Research Associate
School of Aerospace, Mechanical and Mechatronic Engineering

J07 - Mechanical Engineering Building
The University of Sydney

Telephone +61 2 9926 4810
Fax +61 2

Website Biomaterials and Tissue Engineering Research Unit

School of Aerospace, Mechanical and Mechatronic Engineering

Research interests

An enormous number of people worldwide suffer from bone loss due to injury, infection, disease or abnormal development. Treatment requires the regeneration of new bone and, while bone grafts can be taken, only a limited amount of bone is available. Dr Miriam Jackson's research investigates how tissue engineering can safely be used to create a synthetic bone substitute to act as a scaffold for the body to regenerate new bone, gradually degrading as it is replaced by natural bone.

"My research looks specifically at the natural microenvironments necessary for bone cell repair and regeneration, to ensure that compatible biomaterials can be developed.

"Biomaterials play an important role in the regulation of adhesion and growth of a variety of cultured cell types. My current research interest is in 'cellular senescence', a process that involves the permanent arrest of cell division and growth in response to various stressors. These cells remain metabolically active, but they stop dividing and undergo distinct, observable changes.

"Senescence causes loss of tissue-repair capacity, and senescent cells produce pro-inflammatory and matrix-degrading molecules. It has recently been suggested that these cells have a role in age-related bone loss. As such, they are promising therapeutic targets for the prevention of age-related degenerative conditions, including osteoporosis.

"Certain biomaterials can induce senescence-associated changes in cultured human cells, and this must be considered in the selection of a biomaterial for medical application.

"I initially became interested in osteoarthritis research because it affects such a large number of people - including my own parents - and has such a great impact on their lives. I came to understand that the use of tissue engineering to help regenerate damaged tissue and organs was the way of the future, and decided to expand my research into tissue engineering and biomaterials.

I've been working at the University of Sydney since 2010, first in bone and joint research and now, since 2016, in tissue engineering and biomaterials."

Associations

  • 2010-present: Australian & New Zealand Orthopaedic Research Society (ANZORS)
  • 2005-present: Matrix Biology Society of Australia and New Zealand (MBSANZ)
  • 2005-present: Royal North Shore Hospital Staff Scientific Council

Awards and honours

  • Australian Rotary Health Research Fund/Lincoln Foundation for Bone and Joint Research Postgraduate Research Scholarship (2007-2009)
  • New investigator Award for excellence in research by a postdoctoral member of the Matrix Biology Society of Australia and New Zealand (MBSANZ; 2012)
  • MBSANZ Young Investigator Award (2009)
  • Runner-up MBSANZ Dennis Lowther Award for Best Student Poster (2010)
  • Finalist in Young Investigator Award at RNSH/UTS/USYD Research Meeting (2007, 2008, 2010, and 2012)
  • Ramsay Health care/PaLMS International Travel Fellowship (2010)
  • RNSH Beryl and Jack Jacobs International Travel Award (2013)
  • SSC RAMSAY HealthCare Australasian Travel Fellowship (2013)
  • MBSANZ Travel Award (2011)
  • Postgraduate Research Support Scheme Award (2010 and 2008)
  • Douglas Piper Travel Award (2009)
  • Kolling Institute Travel Award (2008)
  • PaLMS Australasian Travel Fellowship (2007)

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Shu, C., Jackson, M., Smith, M., Smith, S., Penm, S., Lord, M., Whitelock, J., Little, C., Melrose, J. (2016). Ablation of Perlecan domain I heparan sulfate reduces progressive cartilage degradation, synovitis, and osteophyte size in post-traumatic osteoarthritis. Arthritis & Rheumatology, 68(4), 868-879. [More Information]
  • Jackson, M., Zaki, S., Ravi, V., Babak, M., Smith, S., Fosang, A., Little, C. (2016). Defining the relationship between joint pathology and pain in osteoarthritis using genetically modified mice. Osteoarthritis and Cartilage, 24, S9-S10.
  • Jackson, M., Babak, M., Smith, M., Jackson, C., Little, C. (2014). Activation of matrix metalloproteinases 2, 9, and 13 by activated protein c in human osteoarthritic cartilage chondrocytes. Arthritis & Rheumatology, 66(6), 1525-1536. [More Information]
  • Jackson, M., Moradi, B., Zaki, S., Smith, M., McCracken, S., Smith, S., Jackson, C., Little, C. (2014). Depletion of protease-activated receptor 2 but not protease-activated receptor 1 may confer protection against osteoarthritis in mice through extracartilaginous mechanisms. Arthritis & Rheumatology, 66(12), 3337-3348. [More Information]
  • El-Hoss, J., Kolind, M., Jackson, M., Deo, N., Mikulec, K., McDonald, M., Little, C., Little, D., Schindeler, A. (2014). Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). Bone, 59, 151-161. [More Information]
  • Jackson, M., Moradi, B., Smith, S., Jackson, C., Little, C. (2013). Protease activated receptor-2 but not PAR-1, modulates synovial macrophage maturation in post-traumatic OA. Osteoarthritis and Cartilage, 21, S61.
  • Chan, B., Fuller, E., Russell, A., Smith, S., Smith, M., Jackson, M., Cake, M., Read, R., Bateman, J., Sambrook, P., Little, C. (2011). Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis and Cartilage, 19(7), 874-885. [More Information]
  • Jackson, M., Smith, M., Smith, S., Jackson, C., Little, C. (2010). Protease activated receptor-2 and activated protein C in cartilage degradation. Osteoarthritis and Cartilage, 18(S2), S90-S90.
  • Jackson, M., Smith, M., Smith, S., Jackson, C., Xue, M., Little, C. (2009). Activation of Cartilage Matrix Metalloproteinases by Activated Protein C. Arthritis & Rheumatology, 60(3), 780-791. [More Information]

2016

  • Shu, C., Jackson, M., Smith, M., Smith, S., Penm, S., Lord, M., Whitelock, J., Little, C., Melrose, J. (2016). Ablation of Perlecan domain I heparan sulfate reduces progressive cartilage degradation, synovitis, and osteophyte size in post-traumatic osteoarthritis. Arthritis & Rheumatology, 68(4), 868-879. [More Information]
  • Jackson, M., Zaki, S., Ravi, V., Babak, M., Smith, S., Fosang, A., Little, C. (2016). Defining the relationship between joint pathology and pain in osteoarthritis using genetically modified mice. Osteoarthritis and Cartilage, 24, S9-S10.

2014

  • Jackson, M., Babak, M., Smith, M., Jackson, C., Little, C. (2014). Activation of matrix metalloproteinases 2, 9, and 13 by activated protein c in human osteoarthritic cartilage chondrocytes. Arthritis & Rheumatology, 66(6), 1525-1536. [More Information]
  • Jackson, M., Moradi, B., Zaki, S., Smith, M., McCracken, S., Smith, S., Jackson, C., Little, C. (2014). Depletion of protease-activated receptor 2 but not protease-activated receptor 1 may confer protection against osteoarthritis in mice through extracartilaginous mechanisms. Arthritis & Rheumatology, 66(12), 3337-3348. [More Information]
  • El-Hoss, J., Kolind, M., Jackson, M., Deo, N., Mikulec, K., McDonald, M., Little, C., Little, D., Schindeler, A. (2014). Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). Bone, 59, 151-161. [More Information]

2013

  • Jackson, M., Moradi, B., Smith, S., Jackson, C., Little, C. (2013). Protease activated receptor-2 but not PAR-1, modulates synovial macrophage maturation in post-traumatic OA. Osteoarthritis and Cartilage, 21, S61.

2011

  • Chan, B., Fuller, E., Russell, A., Smith, S., Smith, M., Jackson, M., Cake, M., Read, R., Bateman, J., Sambrook, P., Little, C. (2011). Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis and Cartilage, 19(7), 874-885. [More Information]

2010

  • Jackson, M., Smith, M., Smith, S., Jackson, C., Little, C. (2010). Protease activated receptor-2 and activated protein C in cartilage degradation. Osteoarthritis and Cartilage, 18(S2), S90-S90.

2009

  • Jackson, M., Smith, M., Smith, S., Jackson, C., Xue, M., Little, C. (2009). Activation of Cartilage Matrix Metalloproteinases by Activated Protein C. Arthritis & Rheumatology, 60(3), 780-791. [More Information]

For support on your academic profile contact .